Abstract
Paroxetine and pindolol have been used in combination to augment the antidepressant response of SSEIs. The rationale given involves the prevention of a negative feedback inhibition of serotonergic neurons but few studies have addressed potential pharmacokinetic interactions. This paper reports on elevated plasma paroxetine concentrations in a 37-year-old depressed woman following the introduction of pindolol. This case study supports the possibility of competitive drug-drug interactions in combinations of paroxetine and pindolol.